SCHEMBL21209660

SCHEMBL21209660

CC(C)NC(=O)c1cccnc1F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.56
MAPK8 P45983 1/20 0.47
PDE4A P27815 2/20 0.46
KCNH2 Q12809 1/20 0.46
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45
ALOX5 P09917 1/20 0.44
RIPK1 Q13546 1/20 0.43
P2RX7 Q99572 1/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PKM P14618 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268777 0.81 P2RX7 (0.65) MAPK8PDE4AKCNH2ADRA1DADRA1A
SCHEMBL26336039 0.81 MAPK8 (0.48) MAPK8PDE4AKCNH2ADRA1DADRA1A
SCHEMBL165047 0.81 MAPK8 (0.48) MAPK8PDE4AKCNH2ADRA1DADRA1A
SCHEMBL8173002 0.81 NAPRT (0.61) NAPRTADRA1DADRA1AADRA1BP2RX7
SCHEMBL24571401 0.80 SMN1; SMN2 (0.56) ALDH1A1LMNAMAPTHPGDSMN1; SMN2
SCHEMBL27986290 0.80 MAPK8 (0.47) MAPK8PDE4AKCNH2ADRA1DADRA1A
SCHEMBL11538360 0.80 PRKCI (0.58) NAPRTMAPK8PDE4AKCNH2ALOX5
SCHEMBL4394779 0.80 HDAC6 (0.51) MAPK8PDE4AKCNH2PDE4BPDE4C
SCHEMBL1585329 0.79 PDPK1 (0.55) NAPRTMAPK8LMNA
SCHEMBL14355564 0.79 KDM4E (0.61) MAPK8PDE4AKCNH2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988477-B2 GCN2 inhibitors and uses thereof MERCK PATENT GMBH (DE) 2021-04-27 US disclosed
WO-2019148132-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 WO disclosed
US-20190233425-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10988477-B2 GCN2 inhibitors and uses thereof EIF2AK4, GCN1, EIF2AK1 NAPRT 3121/4885MAPK8 427/4885PDE4A 3580/4885
US-20190233425-A1 GCN2 INHIBITORS AND USES THEREOF EIF2AK4, GCN1, GCGR NAPRT 1074/4885MAPK8 2566/4885PDE4A 2578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.